Imperial College London

Professor Marc-Emmanuel Dumas

Faculty of MedicineDepartment of Metabolism, Digestion and Reproduction

Chair in Systems Medicine



+44 (0)20 7594 1820m.dumas Website




Mrs Patricia Murphy +44 (0)20 7594 1603




E315BBurlington DanesHammersmith Campus





Professor Marc-Emmanuel Dumas, PhD MEng MSc BEng BSc FRSB FRSC 

Marc-Emmanuel Dumas is Chair in Systems Medicine, jointly appointed between the Department of Metabolism, Digestion and Reproduction and the National Heart and Lung Institute. He is head of the Section of Biomolecular Medicine, hosting state-of-the-art equipment and dedicated teams to metabolomics, crystallisation science and tissue culture. He is also Interim Head of the Division of Systems Medicine translating discoveries in genomics, proteomics, metabolomics and bioinformatics into therapeutic avenues.

He is director of Imperial's Microbiome Network, a cross-faculty multidisciplinary network of excellence, made of >60 PIs and their groups to provide a unique focal point for research, teaching and public engagement activities around the microbiome at Imperial.

Research led by Professor Dumas targets innovative metabolomics approaches to better understand the key challenges in the integrative control of metabolism, blending genomics and microbiomics in systems medicine. He focusses mostly on the role of the microbiome (but not limited to) in metabolic and cardiorespiratory diseases as well as in chronic inflammation, including neuroinflammation, and certain types of cancers.

He is a CNRS Director of Research and group leader at U1283/UMR8199 at the European Genomic Institute for Diabetes in Lille, France and leads the Imperial-University of Lille-CNRS International Research Project in Integrative Metabolism which was launched in 2023. He also holds an Adjunct Professorship at McGill University's Genome Innovation Centre and Department of Human Genetics in Montréal, Canada.

Selected Publications

Journal Articles

Michael BD, Dunai C, Needham EJ, et al., 2023, Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses, Nature Communications, Vol:14, ISSN:2041-1723

Quesada-Vázquez S, Castells-Nobau A, Latorre J, et al., 2023, Potential therapeutic implications of histidine catabolism by the gut microbiota in NAFLD patients with morbid obesity., Cell Rep Med, Vol:4

Puig-Castellvi F, Pacheco-Tapia R, Deslande M, et al., 2023, Advances in the integration of metabolomics and metagenomics for human gut microbiome and their clinical applications, TRAC-Trends in Analytical Chemistry, Vol:167, ISSN:0165-9936

Andrikopoulos P, Aron-Wisnewsky J, Chakaroun R, et al., 2023, Evidence of a causal and modifiable relationship between kidney function and circulating trimethylamine N-oxide, Nature Communications, Vol:14, ISSN:2041-1723, Pages:1-18

Jones RE, Gruszczyk AV, Schmidt C, et al., 2023, Assessment of left ventricular tissue mitochondrial bioenergetics in patients with stable coronary artery disease, Nature Cardiovascular Research, Vol:2, ISSN:2731-0590, Pages:733-745

Pairo-Castineira E, Rawlik K, Bretherick AD, et al., 2023, GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19, Nature, Vol:617, ISSN:0028-0836, Pages:764-768

Belda E, Voland L, Tremaroli V, et al., 2022, Impairment of gut microbial biotin metabolism and host biotin status in severe obesity: effect of biotin and prebiotic supplementation on improved metabolism, Gut, Vol:71, ISSN:0017-5749, Pages:2463-2480

Serger E, Luengo-Gutierrez L, Chadwick JS, et al., 2022, The gut metabolite indole-3 propionate promotes nerve regeneration and repair, Nature, Vol:607, ISSN:0028-0836, Pages:585-592

Fromentin S, Forslund SK, Chechi K, et al., 2022, Microbiome and metabolome features of the cardiometabolic disease spectrum, Nature Medicine, Vol:28, ISSN:1078-8956, Pages:303-+

Dejnirattisai W, Huo J, Zhou D, et al., 2022, SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses, Cell, Vol:185, ISSN:0092-8674, Pages:467-484.e15

Talmor-Barkan Y, Bar N, Shaul AA, et al., 2022, Metabolomic and microbiome profiling reveals personalized risk factors for coronary artery disease, Nature Medicine, Vol:28, ISSN:1078-8956, Pages:295-+

Forslund SK, Chakaroun R, Zimmermann-Kogadeeva M, et al., 2021, Combinatorial, additive and dose-dependent drug-microbiome associations, Nature, Vol:600, ISSN:0028-0836, Pages:500-505

Wickenhagen A, Sugrue E, Lytras S, et al., 2021, A prenylated dsRNA sensor protects against severe COVID-19, Science, Vol:374, ISSN:0036-8075, Pages:1-18

Drake TM, Riad AM, Fairfield CJ, et al., 2021, Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study, The Lancet, Vol:398, ISSN:0140-6736, Pages:223-237

COVID-19 Host Genetics Initiative, 2021, Mapping the human genetic architecture of COVID-19, Nature, Vol:600, ISSN:0028-0836, Pages:472-477

Brial F, Chilloux J, Nielsen T, et al., 2021, Human and preclinical studies of the host-gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health., Gut, Vol:70, ISSN:0017-5749, Pages:2105-2114

Molinaro A, Bel Lassen P, Henricsson M, et al., 2020, Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology, Nature Communications, Vol:11, ISSN:2041-1723

Vieira-Silva S, Falony G, Belda E, et al., 2020, Statin therapy is associated with lower prevalence of gut microbiota dysbiosis, Nature, Vol:581, ISSN:0028-0836, Pages:310-+

Hoyles L, Fernandez-Real J-M, Federici M, et al., 2018, Publisher Correction: Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women, Nature Medicine, Vol:24, ISSN:1078-8956, Pages:1628-1628

Hoyles L, Fernández-Real J-M, Federici M, et al., 2018, Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women., Nat Med, Vol:24, Pages:1070-1080

Hoyles L, Jiménez-Pranteda MJ, Chilloux J, et al., 2018, Metabolic retroconversion of trimethylamine N-oxide and the gut microbiota, Microbiome, Vol:6, ISSN:2049-2618

Plovier H, Everard A, Depommier C, et al., 2017, A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice, Nature Medicine, Vol:23, ISSN:1546-170X, Pages:107-113

Shoaie S, Ghaffari P, Kovatcheva-Datchary P, et al., 2015, Quantifying Diet-Induced Metabolic Changes of the Human Gut Microbiome, Cell Metabolism, Vol:22, ISSN:1932-7420, Pages:320-331

Venkatesh M, Mukherjee S, Wang H, et al., 2014, Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the Xenobiotic sensor PXR and toll-like receptor 4, Immunity, Vol:41, ISSN:1074-7613, Pages:296-310

Blaise BJ, Giacomotto J, Elena B, et al., 2007, Metabotyping of <i>Caenorhabditis elegans</i> reveals latent phenotypes, Proceedings of the National Academy of Sciences of the United States of America, Vol:104, ISSN:0027-8424, Pages:19808-19812

Dumas ME, Wilder SP, Bihoreau MT, et al., 2007, Direct quantitative trait locus mapping of mammalian metabolic phenotypes in diabetic and normoglycemic rat models, Nature Genetics, Vol:39, ISSN:1061-4036, Pages:666-672

Dumas M-E, Barton RH, Toye A, et al., 2006, Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice, Proceedings of the National Academy of Sciences of the United States of America, Vol:103, ISSN:0027-8424, Pages:12511-12516

More Publications